Results 161 to 170 of about 32,925 (256)

Searching for Novel COVID19 Treatments: Towards Covalent TMPRSS2 Inhibitors

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
We designed, synthesised, and evaluated new guanidine derivatives as potential covalent inhibitors of TMPRSS2, a key protease for SARS‐CoV‐2 entry. Computational studies showed that some compounds have improved binding over nafamostat. However, experimentally none effectively blocked viral entry in cell assays, indicating further optimisation is needed.
Marco Minneci, Barbara Farkaš, Adeyemi Rahman, Inga Nehlmeier, Amy Eichmann, Stefan Pöhlmann, Isabel Rozas   +6 more
wiley   +1 more source

Drug-Induced CYP2D6 Phenoconversion Among Individuals with a Psychiatric Disorder: Prevalence and Association with Psychological Distress. [PDF]

Pharmaceutics
Mason ER, Ali MY, Burns RM, Shukla P, Courtenay A, Gibson DS, Murray EK, Kelly C.   +7 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Aficamten in the Chinese Population. [PDF]

Drug Des Devel Ther
Wang Z, Wu X, Jia R, Wang H.
europepmc   +1 more source

CYP2D6 as an Emerging Endogenous Oxidative Stress Modulator in Cardiovascular Disease: Genetic, Pharmacological, and Redox Perspectives. [PDF]

Antioxidants (Basel)
Yang CW, Chen WH, Lee TS.
europepmc   +1 more source

Genetic analysis of CYP2D6 locus of Hong Kong Chinese psychiatric patients

, 1998
The genetically determined polymorphism of debrisoquine hydroxylase (cytochrome P4502D6, CYP2D6) shows marked interethnic differences due to the different distribution of the alleles of the CYP2D6 gene in different populations.
Waye, MMY, Wing, YK, Lam, KL, GarciaBarcelo, MM, Chiu, HFK, Chow, LY   +5 more
core  

CYP2D6 Metabolizer Phenotype and New Persistent Opioid Use After Spine Surgery. [PDF]

Global Spine J
Salman SG, Phadke RA, Anand KK, Guarnieri JW, Waisberg E, Rizkalla J, Lee NJ.   +6 more
europepmc   +1 more source

Recurrent serotonin syndrome during low-dose venlafaxine treatment in a patient with reduced CYP2D6 activity. [PDF]

BMJ Case Rep
Bouti LNA, Graenicher A, Simona A, El Rida El Masri A, Samer CF.   +4 more
europepmc   +1 more source

Genetic Polymorphism of CYP2D6 and MDR1 in breast cancer patients treated with tamoxifen

, 2010
Introduction: Tamoxifen is the drug of choice for the treatment of breast cancer patients who are positive for estrogen receptor. It is metabolized by Cytochrome P450 2D6 (CYP2D6) and the variations in CYP2D6 activity has been reported to have important ...
Harun, R, Hamzah , S, Ngow , Harris Abdullah, Mohamad, NI, Ismail, S   +4 more
core  

Amplicon-based long-read sequencing for accurate CYP2D6 gene deletion and duplication detection using CYP2D7 as a reference gene. [PDF]

Pharmacogenomics J
Tesfamicael KG, Musker M, Adelson DL, Lewis MD.   +3 more
europepmc   +1 more source

Genetic Polymorphisms <i>CYP3A4*22</i>, <i>CYP3A5*3</i>, and CYP2D6 Predicted Phenotypes Are Not Associated with Antipsychotic Treatment Outcomes in Neurotypical Prepubertal Boys with Conduct Disorders. [PDF]

Pharmaceuticals (Basel)
Ivashchenko DV, Che MD, Aysin FR, Tuchkova SN, Korsakov IN, Ianavichiute EI, Ivashchenko MA, Shimanov PV, Kondratieva RV, Shubin AV, Mirzaev KB, Shevchenko YS, Sychev DA.   +12 more
europepmc   +1 more source